title: Multidrug-resistant Escherichia coli bacteremia in cancer patients.
abstract: BACKGROUND
  Multidrug-resistant (MDR) Escherichia coli is a serious threat to cancer patients. We aimed to determine the risk factors associated with the development of MDR E coli bacteremia in cancer patients and the possibility of horizontal transmission.
  
  
  METHODS
  We conducted a 1:2 case-control study of 58 patients with MDR E coli bacteremia. The patient's demographics, clinical characteristics, and antibiotic use were obtained. MDR E coli was defined as resistant strains to quinolones plus 1 of the following: piperacillin, ceftazidime, or cefepime. Repetitive sequence-based polymerase chain reaction (Rep-PCR) was used to identify DNA interstrain similarities.
  
  
  RESULTS
  Conditional multiple logistic analysis showed that admission to the hospital within the 30 days prior to infection and chemotherapy use were risk factors for infection with MDR E coli. Rep-PCR showed that, among the MDR E coli strains recovered, 48.6% showed >95% similarity, representing a possible clonal outbreak. Infection control measures were implemented and controlled this horizontal transmission.
  
  
  CONCLUSIONS
  Prior admission to the hospital and previous chemotherapy were independent risk factors of acquiring MDR E coli. Molecular fingerprinting techniques detected a possible nosocomial clonal outbreak of MDR E coli, which was aborted through infection control measures.
authors.affiliation: University of Texas at Houston-Medical School, Houston, TX, USA.
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Vigil
authors.forename: Javier A
authors.initials: JA
authors.lastname: Adachi
authors.forename: Halim
authors.initials: H
authors.lastname: Aboufaycal
authors.forename: Ray Y
authors.initials: RY
authors.lastname: Hachem
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Reitzel
authors.forename: Ying
authors.initials: Y
authors.lastname: Jiang
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Tarrand
authors.forename: Roy F
authors.initials: RF
authors.lastname: Chemaly
authors.forename: Gerald P
authors.initials: GP
authors.lastname: Bodey
authors.forename: Kenneth V
authors.initials: KV
authors.lastname: Rolston
authors.forename: Isaam
authors.initials: I
authors.lastname: Raad
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000453:epidemiology* / Q000382:microbiology; D015373:Bacterial Typing Techniques; D016022:Case-Control Studies; D016000:Cluster Analysis; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D016172:DNA Fingerprinting; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D017720:Molecular Epidemiology; D009369:Neoplasms / Q000150:complications*; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents